The FDA approved first Spiriva Respimat in the U.S. in September 2015 to be used as a long-term, once-daily maintenance treatment for asthma patients age 12 and older. The medicine is part of a class of drugs called long-acting muscarinic antagonists (LAMA) and the only one of its kind approved for asthma.